BioSpace News Archive

The National Heart, Lung, and Blood Institute also Recognizes the FUEL Trial as an Advancement in CHD for 2019

Almirall, S.A. (ALM) has announced today the execution of an option agreement to acquire Bioniz Therapeutics, Inc. a clinical stage biopharmaceutical company based in Irvine, California, which develops first-in-class peptide treatments that selectively inhibit multiple cytokines to treat immuno-inflammatory diseases and T-cell malignancies

Almirall, S.A. (ALM) and WuXi Biologics (“WuXi Bio”) (2269.HK) have today announced the signing of an agreement.

Almirall, S.A. (ALM), a leading global pharmaceutical company focused on medical dermatology, and 23andMe, the leading consumer genetics and research company, have signed an agreement allowing Almirall to in-license 23andMe’s bispecific monoclonal antibody designed to block all three members of the IL-36 cytokine subfamily.

The reduction in ongoing operating expenses is expected to extend the Company’s cash runway.

Revance Therapeutics, Inc. announced that the company will participate in the 38th Annual J.P. Morgan Healthcare Conference, in San Francisco, CA.

Award is worth up to $3.2 million plus $11.4 million more if certain project milestones are met CARB-X has now invested $179.3 million in 54 projects

Fourth quarter total revenue of approximately $3.0 million, an increase of 67% compared to the prior year period.

The Company’s research and development priorities for its investigational molecules in 2020 are highlighted below.

Expects revenues in the fourth quarter of 2019 to be in the range of $151 million to $152 million.